Kexing Pharmaceutical Releases 2026 Interim Report with Net Profit of 134 Million Yuan

Earnings
โดย Jiemian·CN·Read original
Summary · why it matters

Kexing Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 134 million yuan. The company's total operating revenue was 607 million yuan, down 13.33% from the same period last year. Net cash inflow from operating activities was 25.2456 million yuan, down 15.28% year-on-year. The company's latest asset-liability ratio was 50.49%, gross margin was 54.10%, and diluted earnings per share was 0.68 yuan.

Impact on stocks 1

Others▼ · 1 stocks
© 2026 MarketDXNews